First Author: E.Aydin TURKEY
Co Author(s): 0 0 0 0 0 0 0 0 0
Back to previous
To investigate efficacy of intravitreal enjection of ranizumab and laser photocoagulation for treatment of type I retinopathy of prematurity (ROP) and compare the results in terms of regression and final structural outcome with intravitreal bevacizumab combined with or without conventional transpupillary laser photocoagulation.
The medical records of 111 eyes of 56 infants with Type I and aggressive ROP, who underwent indirect transpupillary laser or / and intraocular injection of bevacizumab (0.03 mL / 0.75mg), were retrospectively reviewed.
56 patients with birth weight 790 to 2700 g (mean,1500.2) and with gestastional age 26 to 34 weeks (mean, 30.2) were included in the study. The timing of bevacizumab injection ranged from postmenstrual age 33.2 to 37 weeks. 18 eyes of 9 patients underwent intravitreal injection of bevacizumab. 41 eyes of 21 patients were treated with transpupillary indirect laser. Intravitreal bevacizumab combined with laser ablasion were perfomed in 52 eyes of 26 patients
Intravitreal bevacizumab combined with or without laser ablasion seems to be highly effective and well tolerated method of treatment in the patients with Type I retinopathy of premature. Inadequate response to treatment of patients with aggressive ROP may need vitreoretinal surgery in a few cases.